Publications by authors named "Li-Xuan Sim"
Cancer Discov
February 2024
Article Synopsis
- * The PlasmaMATCH study found that 4% of patients developed new ESR1 F404 mutations that can disrupt fulvestrant binding, leading to reduced treatment sensitivity, with various combinations of mutations affecting resistance levels.
- * Identifying these F404 mutations provides insights into drug-specific resistance mechanisms to fulvestrant and highlights the potential for new oral estrogen receptor degraders to target complex mutant profiles in ongoing clinical development.
